McBee Moore & Vanik IP, a nationally-recognized leader in chemistry/biotechnology patent prosecution, welcomes its newest team members – Thomas Visone joins as an Associate, and Cindy Hernandez joins as an IP Specialist.
Since the days of working on his Ph.D. in protein science, David Vanik has had an interest in intellectual property and patent law. As Vanik closed in on completing his doctoral research, he began to look at IP within the area of biotechnology.
McBee, Moore & Vanik IP welcomes its newest team members, Miko Andrews and Kurt Buechle!
McBee, Moore & Vanik IP, LLC began in 2016 when partners Susan McBee, C.G. Moore, David Vanik and 12 employees came together to form a new patent law firm with improved client service as the ultimate goal. This year, the firm is celebrating six years together.
Intellectual property is the lifeblood of biopharmaceutical companies. Protection of that information is of paramount importance and it is one reason companies seek legal firms that specialize in intellectual property and patent protection.
Dr. Fussell represents a diverse array of clients in various intellectual property matters, including patent and trademark prosecution and litigation. She performs due diligence, freedom-to-operate, validity, and patentability analyses in the chemical and life sciences industries. She has a wide range of experience in the biotechnology, pharmaceutical, and chemical arts, including medical devices, biofuels, probiotics, plants, herbicides, fertilizers, seeds, nucleic acids, proteins, enzymes, carbohydrates, diagnostics, methods of treating cancer, cancer diagnostics, and agents for treating cancer. Dr. Fussell has negotiated and drafted a wide variety of agreements relating to intellectual property interests, including settlement agreements.
The ISPE Chesapeake Bay Area Chapter Mid-Atlantic Science & Technology (MAST) Virtual Showcase, hosted on May 19th, 2021, provided a platform for life science companies to discuss strategies for addressing challenges in the life science industry.
Over the recent decades, cancer immunotherapy research has made significant advances. In our continued quest to cure cancer, a commercial incentive is necessary to counterbalance the costs and risks associated with the research and development of cancer immunotherapies and to encourage new inventions.
What You’ll Learn? This webinar will be an overview of the United States Patent and Trademark Office’s Cancer Immunotherapy Pilot Program. Duen-Hwa Yan, Ph.D. is a patent agent who works [….]
Intellectual Property / Tech Law Firm McBee, Moore & Vanik Reaches #13 On Top Patent Firms List In Biotechnology & Organics Field McBee, Moore & Vanik Had 247 Patents Issued [….]
